Fed. Circ. Nixes Order Upholding Biogen IP It Also Invalidated
The Federal Circuit on Friday vacated its affirmance of a Patent Trial and Appeal Board ruling that Mylan didn't prove the invalidity of a patent on Biogen's blockbuster multiple sclerosis drug...To view the full article, register now.
Already a subscriber? Click here to view full article